Safety & evidence

PT-141
side effects

A human safety profile exists for the regulated medicine Vyleesi, whose active ingredient is bremelanotide. It does not establish the safety of products sold online as PT-141. Dated 21 November 2026.

Short answerSafety & evidence · 7 min read · Updated 21 Nov 2026

A human safety profile exists for bremelanotide only as the regulated medicine Vyleesi, from trials in premenopausal women; it does not cover online products labelled PT-141. The label reports nausea, flushing, headache and vomiting; 18% who received it stopped because of adverse reactions (2% on placebo), and its role in one acute-hepatitis case could not be excluded.

Key takeaways

  • The human safety findings are from trials and FDA labeling for Vyleesi, not from testing of online products labelled PT-141.
  • In the controlled trials, nausea was reported in 40% of Vyleesi participants and 1.3% of placebo participants; 18% and 2%, respectively, stopped because of adverse reactions.
  • FDA’s label records one acute-hepatitis case in an uncontrolled extension; it says the role of Vyleesi could not be definitively excluded.
  • The main trials enrolled premenopausal women and excluded people with known cardiovascular disease or uncontrolled high blood pressure; the findings do not describe those excluded groups.
  • The label’s Warnings and Precautions section lists three: a temporary rise in blood pressure with a lower heart rate, focal hyperpigmentation, and nausea.

01What has been reported about PT-141 side effects?

If you searched “pt 141 side effects,” the key distinction is between the regulated medicine and products sold online under that name. FDA’s label covers Vyleesi, whose active ingredient is bremelanotide. It does not establish the safety of online PT-141 products.

A shared name does not show that an online product is the medicine tested in clinical trials. The label’s findings describe a regulated product with a defined formulation and study record. They cannot be transferred to a different product simply because its seller uses the same compound name.

SourceWhat it reportsWhat it cannot establish
Controlled trials and FDA labelCommon reported events, comparisons with placebo, and trial discontinuations for Vyleesi.The safety of online products labelled PT-141.
FDA label, uncontrolled extensionOne acute-hepatitis case; the label says Vyleesi’s role could not be definitively excluded.That Vyleesi caused the case, or how often such an event occurs.

“Bremelanotide” is the medicine’s active ingredient. FDA’s label and trial figures concern Vyleesi, not material sold online as PT-141.

02What did the controlled trials report?

FDA’s current Vyleesi label (revised October 2026) summarizes two randomized, placebo-controlled trials lasting 24 weeks, in 1,247 premenopausal women with one diagnosed condition, aged 19 to 56. Its Table 1 lists eleven events reported in at least 2% of those who received it and more often than on placebo. Ten are shown below; the eleventh, the third most common, names the route of administration and is not shown on this site (why). The figures describe participants in those trials, not online PT-141 products.

Reported eventVyleesiPlacebo
Nausea40.0%1.3%
Flushing20.3%0.3%
Headache11.3%1.9%
Vomiting4.8%0.2%
Cough3.3%1.3%
Fatigue3.2%0.5%
Hot flush2.7%0.2%
Paraesthesia2.6%0.0%
Dizziness2.2%0.5%
Nasal congestion2.1%0.5%
Stopped because of adverse reactions18%2%

The label says “the majority of events were reported to be mild (31%) to moderate (40%) in intensity and transient.” That description sits alongside the discontinuation figures: 18% of Vyleesi participants stopped because of adverse reactions, compared with 2% on placebo. The table shows reported events, not a prediction of what a particular person will experience.

The controlled period lasted 24 weeks. The label also describes a 52-week open-label extension in which 684 patients received Vyleesi. Because that extension had no placebo group, it cannot provide a like-for-like comparison with the controlled trials.

The label’s Warnings and Precautions section lists three: temporary increases in blood pressure with decreases in heart rate; focal hyperpigmentation, a darkening of the face, gums or breasts; and nausea. Focal hyperpigmentation was reported in 1% of those who received it in the phase 3 trials and in none on placebo; the label says its resolution was not confirmed in all patients. These label findings apply to Vyleesi.

For a second view of the evidence limits, FDA’s label is the source of record; the trial population and excluded groups are described below.

03What does the FDA label say about serious reports?

In the open-label, uncontrolled extension of one study, the FDA label describes a single acute-hepatitis case. The patient’s liver tests returned to normal four months after Vyleesi was stopped. FDA says another cause was not identified, so the medicine’s role could not be definitively excluded; it also reports no imbalance in liver-test outliers between trial groups.

This is one case in an uncontrolled extension, not a rate or proof of cause. The label reports serious adverse reactions in 1.1% of Vyleesi participants and 0.5% of placebo participants in the controlled trials. It does not say that each serious event was caused by the medicine. One headache event was serious: the label describes “intractable pain leading to hospitalization”.

The label also describes temporary blood-pressure increases, with maximum increases of 6 mmHg systolic and 3 mmHg diastolic, and a heart-rate decrease of up to 5 beats per minute. These changes usually returned to baseline within 12 hours. The regulator’s warnings and contraindications matter alongside the event counts: FDA’s label contraindicates Vyleesi for people with uncontrolled high blood pressure or known cardiovascular disease, and does not recommend it for people at high cardiovascular risk.

These statements concern the regulated medicine, not online products labelled PT-141. They also should not be read as a complete account of every possible event: trial conditions, study length and who was eligible all limit what the results can show.

04What else does the label cover?

The label is the source of record for the regulated medicine. Besides the trial figures above, these parts of it bear on safety.

Three warnings

Section 5 lists a temporary rise in blood pressure with a lower heart rate, focal hyperpigmentation, and nausea. Section 4 rules it out for people with uncontrolled high blood pressure or known cardiovascular disease.

Other sections

Section 7 covers interactions with other medicines. Section 8 covers pregnancy: the label says animal findings point to a potential for fetal harm, and that the few pregnancies in the trials cannot show whether there is a risk.

We summarise the label; we do not reproduce its instructions. The full text is linked in the sources. Nothing in it describes products sold online as PT-141.

05Who was in the main trials, and who was left out?

The label says the two phase 3 trials enrolled 1,247 premenopausal women aged 19 to 56, mean age 39; 86% were White and 12% were Black. FDA’s 2019 review says the trials “excluded women with uncontrolled hypertension or known cardiovascular disease and had limited information on women with well-controlled hypertension”, and that safety “has not been established in postmenopausal women”.

The review does not reproduce the full eligibility rules: it says the complete inclusion and exclusion criteria are in the sponsor’s study reports. We list only the exclusions FDA states. Those rules narrow how far the trial findings can be generalized.

  • The trials do not describe safety in men or postmenopausal women.
  • The findings do not establish safety for people with the conditions excluded from the trials.
  • The Vyleesi trial record does not establish the contents or safety of online products labelled PT-141.

These are study boundaries, not advice about a person’s health. To assess what a laboratory report can and cannot tell you about a tested sample, read how to read a COA.

06What we don’t know

We do not know the safety profile of products sold online as PT-141 from the Vyleesi trials. Those trials tested the regulated medicine in a defined group; they did not test online products labelled PT-141.

We cannot use the single hepatitis case to estimate risk, and the label’s trial figures cannot show how often events occur outside those trials.

The evidence summarized here cannot answer whether the event patterns would be the same in a different group, over a longer period, or with a different product. The label figures describe what was recorded under specific study conditions; they are not a guarantee that an event will or will not occur.

This is a plain-English summary of public documents, checked on 21 November 2026. It is not medical advice.

RefSources

  1. U.S. Food and Drug Administration. Vyleesi prescribing information. Label, revised October 2026 (sections 4, 5, 6.1, 7, 8.1); read 21 Nov 2026. www.accessdata.fda.gov/drugsatfda_docs/label/2026/210557s005…
  2. U.S. Food and Drug Administration. Multidiscipline review and evaluation, NDA 210557. FDA review document, 2019 (PDF p. 28, benefit-risk table; p. 341, where the criteria are referred to the sponsor’s reports); read 21 Nov 2026. www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s…

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

Is there a human safety profile for PT-141?

There is a human safety profile for bremelanotide as the regulated medicine Vyleesi. Those findings do not establish the safety of products sold online as PT-141.

What events were most often reported in the Vyleesi trials?

The most common were nausea (40.0% of those who received it, 1.3% on placebo), flushing, headache and vomiting, plus one event whose name states the route of administration, which this site does not show. The figures describe the regulated medicine in its trials.

Did FDA report a liver-related case?

The FDA label describes one acute-hepatitis case in an uncontrolled extension. FDA says another cause was not identified, so the medicine’s role could not be definitively excluded.

What does the label list as warnings?

Three, in its section 5: a temporary rise in blood pressure with a lower heart rate, focal hyperpigmentation, and nausea. They describe the regulated medicine, not products sold online as PT-141.

Who was left out of the main trials?

The trials enrolled premenopausal women and excluded, among others, people with known cardiovascular disease or uncontrolled high blood pressure. The results therefore do not establish safety for the groups excluded.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page